The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering an interesting story involving useful business lessons.
In Phase 3 with an innovatively delivered drug to treat a deadly complication of ruptured brain aneurysm.
There is no grand plan for a whole year of Companies to Watch (CtW). Each month, a single candidate makes the cut for a single column. Nevertheless, patterns emerge among the CtWs as the year progresses and come into focus as it ends.
On a mission to develop the first FDA-approved, durable-efficacy therapeutic for lactose intolerance
There is an obvious, timely issue with Catabasis that deserves observation but should not eclipse the whole of the company — its Phase 2 candidate for treating DMD.
Dr. Leah Makley, president and CSO, founded ViewPoint based on five years of research she conducted in the lab of cofounder Dr. Jason Gestwicki, where all work is dedicated to protein misfolding, primarily in neurodegenerative diseases such as Alzheimer’s.
“When you’re working for other companies, there are two disadvantages — one, you don’t have full control of your destiny; two, the work tends to come in peaks and valleys.”
Tackling novel treatment and prevention of the most serious allergies with new science and seasoned business talent.
Targeting Parkinson’s dyskinesia and other rare CNS disorders with a novel receptor-binding approach.
Live biotherapeutics to restore microbiomes — in midstage development for vaginal and urinary conditions — with a special focus on women’s health
Developing Safer Opioids In A Market Under Siege
An Update On All The Companies We Profiled In 2015
Needed treatments in vascular injury, osteoarthritis, and maybe more, cleverly targeting the dynamic extracellular matrix.
Reemerging with a licensed drug for a rare neuromuscular disease — and treading carefully to set its price
Vascular Pharmaceuticals is developing a drug to treat diabetic nephropathy. With its partner Janssen, the company has moved its lead mAb compound through preclinical and Phase 1 studies and is now beginning a Phase 2 program.